Showing results (311-320 of 9,661) with videos related to

Sort By:
Pageof 967
Leukemia|May 18, 2019
Correction: Unique CDR3 epitope targeting by CAR-T cells is a viable approach for treating T-cell malignanciesJinqi Huang, Stepanov Alexey, Jian Li, et al.
Leukemia|May 18, 2019
Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphomaLauren Lupino, Tracey Perry, Sandra Margielewska, et al.
Leukemia|October 16, 2019
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trialCharlotte Pawlyn, David Cairns, Martin Kaiser, et al.
Leukemia|October 16, 2019
T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocolP Quist-Paulsen, N Toft, M Heyman, et al.
Leukemia|October 19, 2019
Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation-a phase I/II studyMarthe C J Roex, Peter van Balen, Lothar Germeroth, et al.
Leukemia|April 20, 2022
Utility of the Treatment-Related Mortality (TRM) score to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantationLucas C Zarling, Megan Othus, Brenda M Sandmaier, et al.
Leukemia|April 27, 2022
Development of [211At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignanciesGeorge S Laszlo, Johnnie J Orozco, Allie R Kehret, et al.
Leukemia|April 24, 2022
Leukotrienes promote stem cell self-renewal and chemoresistance in acute myeloid leukemiaAlec W Stranahan, Iryna Berezniuk, Sohini Chakraborty, et al.
Leukemia|October 7, 2021
Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AMLMatthieu Duchmann, Orianne Wagner-Ballon, Thomas Boyer, et al.
Leukemia|October 10, 2021
Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysisPaul J Bröckelmann, Horst Müller, Sarah Gillessen, et al.
Pageof 967